Category: Regulatory Updates

The Regulatory Updates category provides timely coverage of new guidelines, draft revisions, and official communications from authorities such as the EMA, FDA, ICH, USP, and Ph. Eur. It highlights regulatory changes that affect GMP operations, product development, and quality systems.

Each update is presented with context, showing what it means for manufacturers, QA/RA professionals, Qualified Persons, and supply chain leaders. Topics range from revisions to GMP chapters and data integrity expectations to draft guidance on testing and validation.

If you don’t find what you are looking for, try using a different term or contact us.

USP-NF PROPOSED DRAFTS IN PF 51(3)

USP–NF PF 51(3) Draft Published

USP–NF PF 51(3) draft introduces new PAT, content uniformity, parenteral leachables, and CBD standards, enhancing GMP control and regulatory alignment....
usp-233 elemental impurities procedures adopt the harmonized standard

Harmonized Standard for USP <233> Elemental Impurities—Procedures Adopted

Discover the 2025 USP update on elemental impurities: key changes, harmonization across pharmacopeias, and compliance insights....
ich q1 stability testing draft released

ICH Q1 Draft Guideline Released for Comment: Consolidated Stability Framework Moves Forward

ICH Q1 draft released: a unified guideline for stability testing with new content on lifecycle, in-use studies, modelling, and advanced...
Ph.Eur. Proposes rFC Endotoxin Test Integration and Pyrogen Testing Updates

Ph. Eur. Proposes rFC Endotoxin Test Integration and Pyrogen Testing Updates

Ph. Eur. adds rFC to BET (2.6.14) and updates pyrogen testing (5.1.13) to support sustainable, animal-free methods in line with...
USP-NF Pharmacopeial Forum 51 - Draft proposals

USP–NF Proposed Drafts in PF 51(2): Key Highlights and Industry Impact

Discover the key updates in USP–NF PF 51(2), including revisions to chromatography, analytical instrument qualification, microbial contamination control, solubility measurements,...
FDA Draft Guidance: Considerations for Complying with 21 CFR 211.110

FDA Draft Guidance: Considerations for Complying with 21 CFR 211.110

FDA's January 2025 draft on 21 CFR 211.110 outlines CGMP measures for batch uniformity, drug integrity, and advanced manufacturing innovation...
FDA's Transitional Enforcement Policy for Ethylene Oxide Sterilization Facility Changes for Class III Devices

FDA Transitional Enforcement Guidance for Ethylene Oxide Sterilization Facility Changes for Class III Devices

FDA announces a new policy on ethylene oxide sterilization site changes for Class III devices, ensuring supply chain stability and...
ICH E6(R3) Annex 2: Draft Version for Good Clinical Practice in Modern Clinical Trials

ICH E6(R3) Annex 2: Draft Version for Good Clinical Practice in Modern Clinical Trials

Draft ICH E6(R3) Annex 2 provides updated GCP guidelines for modern clinical trials, focusing on decentralized designs, data privacy, and...
USP Introduces New Chapter for Early Adoption Non-Animal Derived Endotoxin Testing Methods

USP Introduces Chapter <86> Bacterial Endotoxins Test Using Recombinant Reagents for Early Adoption

USP releases early adoption guidelines for non-animal endotoxin testing, promoting sustainable recombinant Factor C methods with strict validation standards....
Draft EDQM General Chapter 5.38 Quality of Data

Draft EDQM General Chapter 5.38: Quality of Data

EDQM releases draft chapter 5.38 on data quality in pharma, emphasizing standards, governance, and SME involvement....

BECOME A GMP INSIDER

Stay in touch and be the first to get the latest GMP News!